Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2015 ASCO Annual Meeting /
Subgroup analysis of molecular markers in phase III study of high risk low-grade glioma

29th May - 2nd Jun 2015

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.06.15
Views: 1946
Rating:

Dr Brigitta Baumert - Robert Janker Klinic, Bonn, Germany

Dr Baumert talks to ecancertv at ASCO 2015 about the results of her subgroup analysis of molecular markers of a randomised phase III study in patients with a high risk low-grade glioma.

The analysis investigated how primary chemotherapy using temozolomide compares to standard radiotherapy, if it prolongs progression-free and overall survival, and whether prognostic molecular factors could be defined.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation